A standard protocol for the murine pneumonia model to evaluate treatments for AMR lung infections

Jon Ulf Hansen1, Rakel Arrazuria2, Bernhard Kerscher3, Jennifer L. Hoover3, Carina Vingsbo Lundberg1, Sylvie Sordello4, Vincent Aranzana-Climent5, Isabelle Bekeredjian-Ding6,7, Diarmid Hughes3, Philip Gibbon8, Lena E. Friberg5

1 Bacteria, Parasites & Fungi, Statens Serum Institut, Copenhagen, Denmark. 2 Division of Microbiology, Paul-Ehrlich-Institut, Langen, Germany. 3 Infectious Diseases Research Unit, GSK, Collegeville, Pennsylvania, USA. 4 Infectious Diseases, Evotec, Toulouse, France. 5 Department of Pharmacy, Uppsala University, Uppsala, Sweden. 6 Institute of Medical Microbiology, Immunology and Parasitology, University Hospital Bonn, Bonn, Germany. 7 Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden. 8 Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Discovery Research ScreeningPort, Hamburg, Germany.

Poster contact: JOA@SSI.dk

BACKGROUND & METHOD

Preclinical in vivo PK/PD models play a crucial role in antimicrobial efficacy investigations and provide the basis for the selection of dosing regimens in clinical applications. Differences in the methodology in the preclinical in vivo mouse models used are extensive, thus limiting the results’ comparability and reproducibility and possibly impeding successful translation to the clinic. To facilitate translation, and to accelerate the development of new antibiotics, the COMBINE consortium aims to establish a reliable and globally harmonized preclinical in vivo mouse pneumonia model. Supported by a systematic literature review, we identified important experimental variables and discussed the relevance of these parameters through a workshop with experts in the field. Using a small panel of reference and contemporary clinical Pseudomonas aeruginosa and Klebsiella pneumoniae isolates we report a first test of the application of the standard mouse lung infection protocol.

Figure 1

Table 1

<table>
<thead>
<tr>
<th>Species</th>
<th>No. of isolates tested</th>
<th>Increase in bact. load &lt; 1 log from 2 hrs to endpoint</th>
<th>Lethal ≤12hrs</th>
<th>Suitable strains identified</th>
</tr>
</thead>
<tbody>
<tr>
<td>P. aeruginosa</td>
<td>12</td>
<td>2</td>
<td>8</td>
<td>2</td>
</tr>
<tr>
<td>K. pneumoniae</td>
<td>11</td>
<td>2</td>
<td>0</td>
<td>9</td>
</tr>
</tbody>
</table>

RESULTS

A standard mouse pneumonia protocol was established (figure 1) and applied to test susceptible as well as AMR isolates of species K. pneumoniae and P. aeruginosa isolates (table 1), to identify strains that meet the criteria for use in the COMBINE standard protocol (exemplified in figure 2). Overall, the majority of the tested K. pneumoniae strains met the established virulence criteria whereas the majority of P. aeruginosa strains were either lethal in less than 12 hrs or did not grow in vivo. Ultimately, a selection of isolates that perform appropriately in the model, together with PK/PD data for reference antibiotics vs. these isolates, will be made available to the community for bench-marking new small molecule antibiotics in preclinical development.

![Figure 1](image1)

![Figure 2](image2)

Figure 2. Mean ± SD CFU values of examples of P. aeruginosa and K. pneumoniae isolates that meet (+) or fail (-) the criteria of the model. CFU values at t=0 were quantified from the inoculum, not mouse lungs; isolates with endpoints before 26 hrs were euthanized due to clinical score

We thank the GNA NON project and in particular Sharon Evans and Pippa Griffin from the North Bristol NHS Trust for kindly sharing clinical P. aeruginosa and K. pneumoniae isolates. Also Frederikke Rosenberg, Karen Juhi, Sandra N.B. Jensen and Tina S. Lundager (Statens Serum Institut) for expert technical assistance. All animal studies were ethically reviewed and carried out in accordance with European Directive 2010/63/ECC and the GSK Policy on the Care, Welfare and Treatment of Animals.

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 853967. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA companies’ kind contribution. This communication reflects the views of authors from the COMBINE consortium and neither IMI nor European Union and EFPIA are liable for any use that may be made of the information herein.

Abstract No. EA60